sccs_opinions
Max up to 4% (as permitted under Annex VI/18 at time of opinion; now banned)
safe with restrictions (at time of opinion; subsequently banned)
Key concerns: Endocrine disrupting potential concerns raised; thyroid and estrogen effects noted; SCCP found borderline safety but concluded safe at 4% in 2008; later SCCS/1639/21 concluded not safe and led to ban
Opinion date: 24 June 2008